Piper Jaffray Companies reiterated their hold rating on shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) in a report published on Friday morning. Piper Jaffray Companies currently has a $7.00 price target on the stock.
Other research analysts have also issued reports about the company. Canaccord Genuity set a $10.00 price target on Endo International PLC and gave the company a hold rating in a report on Monday, August 14th. Citigroup Inc. decreased their target price on Endo International PLC from $9.00 to $7.00 and set a neutral rating for the company in a research note on Friday. BMO Capital Markets decreased their target price on Endo International PLC from $11.00 to $10.00 and set a market perform rating for the company in a research note on Friday. Mizuho reaffirmed a buy rating on shares of Endo International PLC in a research note on Friday. Finally, Cantor Fitzgerald decreased their target price on Endo International PLC from $9.00 to $7.00 and set a neutral rating for the company in a research note on Friday. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have given a buy rating to the stock. The stock has an average rating of Hold and an average price target of $11.67.
Shares of Endo International PLC (NASDAQ:ENDP) traded up $0.84 on Friday, hitting $6.93. The stock had a trading volume of 12,136,900 shares, compared to its average volume of 8,194,132. The firm has a market capitalization of $1,547.57, a price-to-earnings ratio of 1.43 and a beta of 0.53. The company has a debt-to-equity ratio of 10.20, a current ratio of 1.02 and a quick ratio of 0.80. Endo International PLC has a 52 week low of $5.77 and a 52 week high of $18.63.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Thursday, November 9th. The company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.06. The company had revenue of $786.90 million for the quarter, compared to analyst estimates of $794.93 million. Endo International PLC had a positive return on equity of 56.97% and a negative net margin of 126.97%. The company’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same period last year, the company earned $1.01 earnings per share. research analysts expect that Endo International PLC will post 3.54 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/11/12/endo-international-plcs-endp-hold-rating-reaffirmed-at-piper-jaffray-companies.html.
In other Endo International PLC news, CEO Paul Campanelli bought 6,500 shares of the stock in a transaction on Monday, August 14th. The shares were purchased at an average price of $7.71 per share, with a total value of $50,115.00. Following the acquisition, the chief executive officer now directly owns 213,620 shares of the company’s stock, valued at approximately $1,647,010.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders acquired a total of 16,000 shares of company stock worth $125,460 in the last ninety days. Insiders own 0.50% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENDP. James Investment Research Inc. acquired a new stake in Endo International PLC in the 2nd quarter valued at approximately $113,000. Blair William & Co. IL acquired a new stake in Endo International PLC in the 2nd quarter valued at approximately $126,000. LMR Partners LLP acquired a new stake in Endo International PLC in the 3rd quarter valued at approximately $148,000. Point View Wealth Management Inc. grew its holdings in Endo International PLC by 16.6% in the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after buying an additional 1,900 shares during the last quarter. Finally, Riverhead Capital Management LLC grew its holdings in Endo International PLC by 64.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock valued at $168,000 after buying an additional 5,887 shares during the last quarter. 90.32% of the stock is currently owned by hedge funds and other institutional investors.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.